- Home
- RIGL vs RAC Comparison
RIGL vs RAC Comparison
Compare RIGL & RAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- RAC
- Stock Information
- Founded
- RIGL 1996
- RAC 2024
- Country
- RIGL United States
- RAC United States
- Employees
- RIGL N/A
- RAC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- RAC
- Sector
- RIGL Health Care
- RAC
- Exchange
- RIGL Nasdaq
- RAC Nasdaq
- Market Cap
- RIGL 335.5M
- RAC 302.3M
- IPO Year
- RIGL 2000
- RAC 2025
- Fundamental
- Price
- RIGL $41.50
- RAC $10.30
- Analyst Decision
- RIGL Buy
- RAC
- Analyst Count
- RIGL 5
- RAC 0
- Target Price
- RIGL $38.20
- RAC N/A
- AVG Volume (30 Days)
- RIGL 845.0K
- RAC 115.0
- Earning Date
- RIGL 08-05-2025
- RAC 01-01-0001
- Dividend Yield
- RIGL N/A
- RAC N/A
- EPS Growth
- RIGL N/A
- RAC N/A
- EPS
- RIGL 5.43
- RAC N/A
- Revenue
- RIGL $267,921,000.00
- RAC N/A
- Revenue This Year
- RIGL $14.41
- RAC N/A
- Revenue Next Year
- RIGL $15.97
- RAC N/A
- P/E Ratio
- RIGL $7.64
- RAC N/A
- Revenue Growth
- RIGL 105.62
- RAC N/A
- 52 Week Low
- RIGL $12.00
- RAC $10.00
- 52 Week High
- RIGL $43.72
- RAC $10.70
- Technical
- Relative Strength Index (RSI)
- RIGL 86.20
- RAC N/A
- Support Level
- RIGL $38.43
- RAC N/A
- Resistance Level
- RIGL $41.25
- RAC N/A
- Average True Range (ATR)
- RIGL 2.50
- RAC 0.00
- MACD
- RIGL 0.89
- RAC 0.00
- Stochastic Oscillator
- RIGL 89.85
- RAC 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About RAC Rithm Acquisition Corp. Class A Ordinary Shares
Rithm Acquisition Corp is a blank check company.